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Data resource basics
The UK Cystic Fibrosis Registry is a national, secure, central-
ized database sponsored and managed by the Cystic Fibrosis
Trust, with UK National Health Service (NHS) research eth-
ics approval and consent from each person for whom data
are collected. First established in 1995, it records longitu-
dinal health data on all people with cystic fibrosis (CF) in
England, Wales, Scotland and Northern Ireland, and to date
has captured data on over 12000 individuals.
Cystic fibrosis is an inherited, chronic, progressive con-
dition occurring in around 1 in 2500 live births in the UK,
with around 200–300 new diagnoses annually. Children
are generally diagnosed in the first few months of life with
universal newborn screening being implemented in 2007 in
the UK, though some people are diagnosed into adulthood.
For instance, 29 people aged over 16 years were diagnosed
with CF in the UK in 2015.1 Patients diagnosed with CF
subsequently require intensive support from family and
health care services. Most patients die prematurely from
their disease through respiratory failure, and in the 1930 s
and 40 s survival beyond childhood was rare.2 There have
been impressive improvements in survival over subsequent
decades; for instance, the median life expectancy of chil-
dren with cystic fibrosis born in 1990 was estimated to be
40 years, double that of estimates 20 years earlier.3
In the UK, children with CF are treated in one of 33 spe-
cialist centres (associated with over 100 smaller network
clinics). At between 16 years and 18 years of age, children
transfer to one of 27 adult specialist centres. All centres
and network clinics routinely collect data in a standardized
fashion. When patients with CF attend a new CF centre in
the UK, they or their parents consent to information on
their health and treatment being collected and stored in the
CF Registry. The patient information and consent form
also covers the issue of linking registry data to the UK
Office for National Statistics. When transitioning to adult
services, the young adult is given the opportunity to con-
firm or withdraw consent. People with CF will also re-
consent if they change their primary centre of care. The
Registry records information about the health and
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treatment, and health care use (e.g. hospital days) and out-
comes of patients from diagnosis onwards. The Registry
contains personal identifiers, seen only by the local centre
team and CF Registry data managers. Reports generated
by the Registry are used as the evidence base for commis-
sioning care and pharmacovigilance of new therapies.
Harnessing the rich data in CF registries in the UK and be-
yond offers the opportunity to improve the lives of patients
with CF now, and to establish an essential data resource
for future research.
History of the registry
The UK CF Registry started as the UK CF Database, which
was established at the University of Dundee, Scotland, in
1995. Initially data were collected from 56 paediatric and
adult CF clinics, using standardized forms, and validated
through a system of double data entry, range checking and
error correction.4 Between 2005 and 2007, the Cystic
Fibrosis Trust rolled out a national UK-wide web-based sys-
tem, following new ethics approval and re-consent of all pa-
tients, with migration of the data to a new system. The data
collection system thus changed from a paper-based return
system to using the online ‘PortCF’ software which mim-
icked the data collection and storage system used by the
Cystic Fibrosis Foundation Patient Registry in the USA.
During this transfer there was extensive retrospective data
cleaning and checking. In 2012. the Registry commenced
production of reports that are used by the NHS England to
make payment by results (PbR) tariff payments to CF
centres. Linking the Registry to NHS reimbursement proc-
esses significantly improved the completion of data.
Recently, the PortCF system has been replaced by new UK
CF Registry software developed by the UK-based web de-
velopment specialists Net Solving Ltd. The new system has
been developed with patient involvement and includes
interactive elements that may, in due course, allow patients
to access their own data. The UK CF Registry has thus far
led to the production of 10 annual reports, with the latest
2015 data published in August 2016.1 The UK CF Registry
Steering Committee was established in 2007 to oversee de-
velopment of the Registry, annual reports and research gov-
ernance; it meets regularly and includes medical, sponsor
(Cystic Fibrosis Trust), commissioner, statistician, patient
and parent representation. It has recently set up a sub-
committee, the UKCF Registry Research Committee, to
allow more detailed oversight and governance of this area.
Data collected
The dataset contains: time-invariant variables, such as sex,
genotype and date of birth; and longitudinal variables that
change over time, such as weight and measures of lung
function. CF patients are seen in the outpatient clinic for a
comprehensive annual review, including evaluation of clin-
ical status, pulmonary function, microbiology of respira-
tory tract secretions and use of major CF-related therapies.
The minimum data collection requirement for the UK CF
Registry is an annual dataset, usually taken from the an-
nual review clinic visit. The data collected at the annual re-
view are indicated in the dataset, and can be distinguished
from ‘encounter’-based data collected in the interval be-
tween clinic visits. In this data resource profile, we only de-
scribe the annual review data which are the basis of the
CF-Epinet dataset described below. Some clinics use the
Registry to collect encounter data, but these are not sys-
tematically collected. Thus the data in the registry mostly
derive from the annual review, rather than being
encounter-based, though the annual review data include
certain summaries of information since the previous re-
view–for example. the number of days a patient has been
on intravenous antibiotics and the best % forced epiratory
volume in 1 s (FEV1) recorded in the previous year. Data
are collected in key areasincluding: demographics (includ-
ing genotyping and diagnosis data), hospital admissions
and intravenous therapies, pulmonary function, chronic
medications, culture and microbiology, health complica-
tions, nutritional assessment, physiotherapy, smoking,
socioeconomic status and outcomes (death and trans-
plants).4 Templates of the data collection forms showing
all variables collected are available to download from the
CF Registry portal as well as from the Cystic Fibrosis Trust
Registry web page. 5
Coverage
Of the 22 countries providing data to the wider European
Cystic Fibrosis Society Patient Registry,6 the UK CF
Registry is the largest national database and the most com-
plete in terms of coverage. Currently data on 12 201 pa-
tients are captured in the UK Registry (alive, dead or lost
to follow-up) with 9734 (79.8%) still in follow-up at the
end of 2015. In total there are data on over 100 000 annual
assessments. Figure 1 shows the cumulative count of pa-
tients captured in the Registry by year, including patients
who have died. Figure 1 also shows annual counts of an-
nual reviews, deaths, and losses to follow-up (defined as
patients with no annual reviews for 2 years in succession).
The number of people captured in the dataset has increased
year on year, with increases coinciding with the move to
the web-based system, followed by the incentivizing of
data collection for NHS funding purposes in England and
Scotland in 2012. The number of patients for whom a
‘complete’ dataset, defined as the data required to produce
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the range of key clinical outcomes relating to growth, lung
function and treatment presented in the annual reports,
was recorded at 82% in 2009, and this has increased year
on year, with the figure up to 89% for the latest (2015) an-
nual report.1
For the purposes of illustrating the longitudinal struc-
ture of the data, we consider the patient’s weight, since
weight is one of the most commonly collected outcomes in
the dataset, collected at 117 482 annual reviews on 12201
patients between 1996 up to 2015 in the UK. A total 0f
78% of individuals had five or more weight measurements,
with a mean number of nine measurements. Figure 2 shows
all patient’s weight data, presented as age-standardized
z-scores7 plotted against age, with randomly selected indi-
vidual trajectories highlighted. Z-scores in adults were cal-
culated assuming the weight-for-age distribution at age 19.
Quality
Data quality is assured through a number of mechanisms.
For clinicians and others entering data into the Registry,
up-to-date user guides are available on the UK CF Registry
portal and contextual help text is available next to individ-
ual variables, to instruct users as to how to interpret the
question and use the software. Training videos are also
available to assist clinicians in entering and monitoring
data from their own clinic. Software functionality encour-
ages CF centres to monitor their own data on an ongoing
basis. A quality dashboard gives users an on-demand, at a
glance view of their data completeness as well as
summaries of key clinical indicators such as lung function,
with live benchmarks against national averages.
The Registry data collection software performs data
validation checks at point of entry. These include: the
enforcing of mandatory data; range checks for clinically
valid values; ensuring that only valid characters are
entered; and text and visual prompts to ensure that data
(including dates) are not illogical or conflicting and to en-
courage completion of core data. The Cystic Fibrosis Trust
also supports a Registry Annual Meeting in July each year.
This event is free to attend for all CF centre employees
who enter data onto the Registry, and is designed to show-
case current registry research and offer training and best
practice-sharing opportunities.
The Cystic Fibrosis Trust Registry team perform train-
ing and validation visits at CF centres, to ensure that users
are aware of data entry guidelines and encouraged to im-
prove the completeness and accuracy of their data. After
the data entry deadline on the 31 January each year,
Registry data managers and statisticians perform a variety
of data cleaning checks, such as tracking of patient transi-
tion from paediatric to adult clinics. Where longitudinal
analysis detects apparent inconsistencies that cannot be
automatically cleaned, the Registry team liaise directly
with CF centres to check and, where relevant, correct data.
Data resource use
Registry studies have been crucial in informing our under-
standing of the epidemiology, changing demographics,
Figure 1. Cumulative count of individuals captured in the registry and number with annual review data in each year (left panel). Count of deaths and
losses to follow-up (right panel).
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outcomes and treatments in CF. Two examples of analyses
of UK Registry data are provided in the text box.
In addition to epidemiological studies, the UK CF
Registry team produce reports on long-term drug safety
required by the European Medicines Agency (EMA). These
reports contain anonymized, aggregated data and allow
safety- and efficacy-monitoring of new therapies for cystic
fibrosis. There is also a facility to support Registry-based
clinical trials. For instance, the UK CF Registry is cur-
rently, via a specially designed study module, running a CF
Registry-based clinical trial, the cystic fibrosis (CF) anti-
staphylococcal antibiotic prophylaxis trial (CF START): a
randomized registry trial to assess the safety and efficacy
of flucloxacillin as a long-term prophylaxis agent for in-
fants with CF.8
Making use of the Port-CF system, with similar vari-
ables collected in the UK and USA, Goss and col-
leagues compare CF outcomes and use of treatments
between the two countries. Their cross-sectional ana-
lysis suggested that the USA does better in terms of
lung function in children, and one hypothesis raised is
that this may be due to more intensive treatment in
the early years in the USA.9
Studies making use of data from the UK CF Registry
are increasing,5–11,15,16 but relatively few have made
use of the longitudinal nature of the data. One longitu-
dinal study has assessed the impact of socioeconomic
status on outcomes and treatment use in the UK popu-
lation.7 More disadvantaged children with CF in the
UK were found to have significantly worse growth and
lung function, and were more likely to have chronic P.
aeruginosa infection. There was evidence that in the
NHS, clinicians in making decisions about treatments
for children take deprivation as well as disease status
into account, and this may mitigate some effects of so-
cial disadvantage. The study raises concerns about the
provision of therapies such as DNase to people living
in disadvantaged areas.
The Cystic Fibrosis Epidemiological Network
(CF-EpiNet)
In recognition of the potential to better harness data from
registries to improve patient outcomes, the Cystic Fibrosis
Trust have funded a Strategic Research Centre (CF-EpiNet)
focused on CF data and epidemiology. CF-EpiNet is focused
on: Registry enhancement; application of state-of-the art
Figure 2. Spaghetti plot for weight z-score versus age, illustrating the longitudinal nature of the data collected in the UKCF Registry. Each dot (n¼ 117
482) represents a weight z-score measure on a person in the dataset. The smoothed cross-sectional population average is shown in red (95% confi-
dence intervals) and 50 randomly selected individual trajectories are in black.
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statistical modelling techniques to longitudinal data; and
economic modelling. An important part of this project will
involve data cleaning, harmonization of variables over time
and the generation of a research-ready ‘CF-EpiNet’ dataset.
Algorithms and code for cleaning the data should allow re-
searchers to a obtain more up-to-date version of the data,
with extra years of longitudinal data added.
CF-EpiNet aims to develop a holistic view of how CF
impacts on patients across the life course, and to identify
modifiable targets for clinical and policy intervention (e.g.
early life exposures, access to therapies, educational sup-
port) by the application of modern statistical methods for
longitudinal analysis and by direct comparisons with inter-
national datasets. Key aims are to optimize the scientific
value of the Registry by linking it to data from other ad-
ministrative datasets, and by undertaking a quality of life
survey. The quality of life component of the project has
been developed within a portal, ‘My CF Registry’, allowing
patient-reported outcome measures to be entered directly
by patients. In the future, this portal could enable people
with CF to view their historical clinical data, self-report
data and opt into additional uses of Registry data that will
enhance the value of the Registry to the CF community.
Strengths and weaknesses of the Registry
Registries can provide valuable insights into variations in
clinical outcomes, quality of care and the safety and/or ef-
fectiveness of treatments. However, the usefulness and ap-
plicability of Registry data rely on the quality of several
aspects: the measurements and information recorded; the
accuracy of data input, data storage and export; and ap-
propriate data analysis and interpretation, bearing in mind
the inherent shortcomings of routinely collected data.17,18
A key strength of the UK CF Registry is the population-
level coverage. In the UK, the Registry is estimated to
capture almost all of the CF population; any consenting
patients attending NHS clinics will have annual data rou-
tinely collected into the database. Furthermore, the dataset
is of high quality, with robust systems for data cleaning
and checking. The UK dataset represents one of the largest
national CF datasets outside the USA,17 and this provides
the statistical power to precisely estimate parameters of
interest. The UK CF Registry contains a wide range of clin-
ical, health care and social information, allowing for ro-
bust adjustment for appropriate covariates in statistical
analyses. A further consequence of the high level of popu-
lation coverage in the UK, coupled with a universal health
care system, is that analyses can cover individuals across
the full range of the socioeconomic spectrum in the UK.
The unique Registry identification number facilitates longi-
tudinal research, an advantage over other registries which
rely on yearly snapshot population data. In addition, the
coverage for core variables summarized in the annual re-
ports, such as weight and %FEV1, are high.
One key limitation of the UK CF Registry compared
with some other CF registries is that it at present manda-
torily requires only annual review data, rather than all clin-
ical encounters, which limits some of the research
questions that can be addressed. There are also some gaps
in information collected, such as primary and secondary
non-CF-related care episodes. Data linkage to other na-
tional datasets has been a long-standing aim of the UK CF
Registry, and the CF-EpiNet project is exploring relevant
linkages to include those with primary and secondary care
databases, mortality data, census data, databases holding
area-level information on environmental exposures and the
National Pupil Database. For each of these, linkage poses
different ethical and practical challenges and strict data
protection guidelines are followed.
Common to many registries, in contrast to inception co-
horts, survival times of individuals in the UK dataset are
subject to left truncation because the Registry captures the
living population at the inception of the Registry and inci-
dent cases subsequent to this. This leads to potential sur-
vivor bias, whereby the living population at the outset of the
Registry represented healthier individuals from their respect-
ive birth cohorts who have survived to the point of being
included in the dataset. This is a common issue in registry
analyses. There are strong cohort effects in the data, which
are likely to represent a mixture of survivorship effects, and
the ‘true’ cohort effects representing improving treatment
over time, as demonstrated in other studies.7,19 With longer
follow-up, as the UK CF Registry matures, separating age
and cohort effects will become possible and eventually it
will be possible to analyse incident individuals alone, ensur-
ing that the longitudinal experience of all individuals from a
particular birth cohort will be captured.18 Making projec-
tions about outcomes for people with CF in the future will
always be a challenge, in particular because there have been
and continue to be substantial improvements in treatment
and care over a relatively short time period.
Data resource access
All the information in the UK CF Registry is held confiden-
tially and available only to two assigned members of the
UK CF Registry data management team. Clinical teams
can access only the data that relate to patients in their care,
and are required to validate their identity using two-factor
authentication before logging into the system. The system
also provides an audit trail for any data access. The CF
Registry is registered under the Data Protection Act (1998)
which was designed to provide a legal framework upon
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which to protect the privacy of personal data when used
with information technology.
Data are stored within secure Microsoft Azure data
centres in Ireland and Holland, which are certified as suit-
able for official government data, including health care
data. The database servers are not directly connected to
the internet; all administrative access is via a secure VPN
connection which requires a dedicated security certificate
to allow access. The application hosting environment has
been security-tested by certified security consultants. All
data are viewed and entered via a secure HTTPS web
portal.
NHS Research Ethics approval (Huntingdon Research
Ethics Committee 07/Q0104/2) has been granted for the
collection of data into the UK CF Registry. Each patient or
their parent provided written informed consent for collec-
tion of data in the registry as outlined above, and this in-
cludes for use of pseudonymized data in research. There is
a formal process for requesting access to the UK CF regis-
try, and an application form can be found using this link:
[www.cysticfibrosis.org.uk/registry]. In 2016 there were
29 applications for access to anonymized Registry data; 26
were approved after review by the UK CF Registry
Research Committee, with the remaining three requests
being withdrawn or rejected.
Profile in a nutshell
• The UK Cystic Fibrosis Registry is a national, secure,
centralized database sponsored and managed by the
Cystic Fibrosis Trust. It was set up to record longitu-
dinal health data on people with cystic fibrosis (CF)
in England, Wales, Scotland and Northern Ireland.
Containing data on almost all people with CF in the
UK, it is one of the largest and most complete na-
tional CF databases available.
• First established in 1995, to date the UK CF Registry
has captured data on over 12000 individuals with a
combined total of more than 100 000 annual
assessments.
• Patient data are recorded in the Registry after a con-
firmed CF diagnosis and consent for data to be col-
lected has been obtained. Subsequently, health data
are added to the Registry at every annual
assessment.
• Data are collected in several key areas including:
demographics (including genotyping andand diagno-
sis data), hospital admissions and intravenous thera-
pies, pulmonary function, chronic medications,
culture andand microbiology, health complications,
nutritional assessment, physiotherapy, lifestyle and
outcomes (death and transplants).
• There is a formal process for requesting access to
the UK CF Registry. An application form and more
details can be found using the following link: [https://
www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-regis
try/apply-for-data-from-the-cf-registry].
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